Cocrystal Pharma provides update on development of CDI-988, CC-42344

Cocrystal Pharma provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A. “We are encouraged that the preliminary data of the ongoing Phase 2a and Phase 1 studies showed CC-42344 and CD-988 were well-tolerated with favorable safety profiles,” said Sam Lee, Ph.D., Cocrystal’s President and co-CEO. “We see great promise with both of these drug candidates as potential effective oral treatments for highly contagious, pandemic viruses, while also providing significant market opportunities for Cocrystal.” The Company reports favorable preliminary data of CDI-988 from the single-ascending dose cohorts of the clinical study. Cocrystal expects to report topline results from the Phase 1 study this year. The Company reports favorable tolerability and safety in the first cohort of the Phase 2a influenza A challenge study of CC-42344 and expects to report topline results from the Phase 2a clinical study this year